PV Bulletin

TGA Consultation on Radiopharmaceutical Regulation in Australia

The TGA is seeking feedback on regulatory settings for radiopharmaceuticals, which may impact safety monitoring and compliance obligations.

Primary source: https://www.tga.gov.au/resources/consultation/consultation-radiopharmaceutical-regulation-australia

PV Impact Brief

MonitoringConfidence: high

What changed

TGA opened a consultation on radiopharmaceutical regulation, seeking feedback on current settings and potential reforms.

Why it matters

Radiopharmaceuticals are used for serious conditions like cancer and cardiovascular disease. Changes may alter safety monitoring and compliance obligations for manufacturers and suppliers.

Action needed

Review the consultation document and consider submitting feedback by 2026-07-31. Monitor for final regulatory changes affecting radiopharmaceutical safety monitoring and compliance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-07-31.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-06-05
Consultation deadline
2026-07-31
Policy change
The TGA is seeking feedback on the current regulatory settings for radiopharmaceuticals in Australia. The consultation aims to understand how existing legislation and radiation safety frameworks operate in practice and identify areas for potential reform.

Key changes

The consultation covers regulatory settings across Commonwealth therapeutic goods legislation and state/territory radiation safety frameworks. It may lead to changes in licensing, manufacturing, and safety monitoring requirements for radiopharmaceuticals.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsPharmacovigilance Operations

PV impact

Stakeholders involved in the manufacture or supply of radiopharmaceuticals should review the consultation to understand potential changes in safety monitoring and compliance obligations for these specialized products.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review the consultation document and consider submitting feedback by 2026-07-31. Monitor for final regulatory changes affecting radiopharmaceutical safety monitoring and compliance.

The TGA launched a consultation on radiopharmaceutical regulation, covering Commonwealth and state/territory frameworks. Stakeholders should review potential changes in licensing, manufacturing, and safety monitoring by the deadline of 2026-07-31.

What changed: TGA opened a consultation on radiopharmaceutical regulation, seeking feedback on current settings and potential reforms.

Why it matters: Radiopharmaceuticals are used for serious conditions like cancer and cardiovascular disease. Changes may alter safety monitoring and compliance obligations for manufacturers and suppliers.

Practical implication: Review the consultation document and consider submitting feedback by 2026-07-31. Monitor for final regulatory changes affecting radiopharmaceutical safety monitoring and compliance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Consultation#Radiopharmaceuticals#Australia#TGA#Therapeutic Goods Administration (TGA)#guidance#policy-change

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward